Cargando…

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country

BACKGROUND: Although guidelines for prophylactic human papillomavirus (HPV) vaccination recommend two doses for girls ages 9–14 years, several studies have demonstrated similar protection with one dose. Our objective was to evaluate the long-term health and economic impacts of routine one-dose HPV v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Emily A., Campos, Nicole G., Sy, Stephen, Regan, Catherine, Kim, Jane J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066173/ https://www.ncbi.nlm.nih.gov/pubmed/29807710 http://dx.doi.org/10.1016/j.vaccine.2018.04.061

Ejemplares similares

Health and economic impact of rotavirus vaccination in GAVI-eligible countries
por: Kim, Sun-Young, et al.
Publicado: (2010)

Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries
por: Ochalek, Jessica, et al.
Publicado: (2020)

Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden
por: Kim, Sun-Young, et al.
Publicado: (2011)

Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2021)

Gavi HPV Programs: Application to Implementation
por: Hanson, Celina M., et al.
Publicado: (2015)

Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
por: Bilcke, Joke, et al.
Publicado: (2019)

The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study
Publicado: (2019)

Evaluating Global Health Partnerships: A Case Study of a Gavi HPV Vaccine Application Process in Uganda
por: Kamya, Carol, et al.
Publicado: (2016)

Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries
por: Levin, Ann, et al.
Publicado: (2014)

Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects
por: Botwright, Siobhan, et al.
Publicado: (2017)

Gavi Support for Typhoid Conjugate Vaccines: Moving From Global Investments to Country Introduction
por: Soble, Adam, et al.
Publicado: (2020)

Now or later: Health impacts of delaying single‐dose HPV vaccine implementation in a high‐burden setting
por: Burger, Emily A., et al.
Publicado: (2022)

Challenges to sustainable immunization systems in Gavi transitioning countries
por: Cernuschi, Tania, et al.
Publicado: (2018)

Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries
por: Li, Xiao, et al.
Publicado: (2020)

Potential effectiveness of a therapeutic HPV intervention campaign in Uganda
por: Spencer, Jennifer C., et al.
Publicado: (2021)

Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys
por: Burger, Emily A., et al.
Publicado: (2014)

Post-GAVI sustainability of the Haemophilus influenzae type b vaccine program: The potential role of economic evaluation
por: Le, Phuc, et al.
Publicado: (2016)

Vaccination coverage rates and predictors of HPV vaccination among eligible and non-eligible female adolescents at the Brazilian HPV vaccination public program
por: Faisal-Cury, Alexandre, et al.
Publicado: (2020)

The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models
por: Baral, Ranju, et al.
Publicado: (2020)

Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol
por: Löwensteyn, Yvette N., et al.
Publicado: (2021)

How to evaluate the implementation of complex health programmes in low-income settings: the approach of the Gavi Full Country Evaluations
por: Soi, Caroline, et al.
Publicado: (2020)

Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?
por: Luthra, Karuna, et al.
Publicado: (2021)

Correction to: Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol
por: Löwensteyn, Yvette N., et al.
Publicado: (2021)

Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2019)

Exploring the influence of the Global Fund and the GAVI Alliance on health systems in conflict-affected countries
por: Patel, Preeti, et al.
Publicado: (2015)

Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries
por: Saxenian, Helen, et al.
Publicado: (2015)

Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway
por: Burger, Emily A, et al.
Publicado: (2017)

Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study
por: Birger, Ruthie, et al.
Publicado: (2022)

Evaluating Country Performance After Transitioning From Gavi Assistance: An Applied Synthetic Control Analysis
por: Kolesar, Robert John, et al.
Publicado: (2023)

The GAVI Alliance and the ‘Gates approach’ to health system strengthening
por: Storeng, Katerini T.
Publicado: (2014)

Ensuring vaccine potency and availability: how evidence shaped Gavi's Immunization Supply Chain Strategy
por: Prosser, Wendy, et al.
Publicado: (2022)

Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study
por: Donken, Robine, et al.
Publicado: (2018)

Has Gavi lived up to its promise? Quasi-experimental evidence on country immunisation rates and child mortality
por: Jaupart, Pascal, et al.
Publicado: (2019)

Advancing Immunization Coverage and Equity: A Structured Synthesis of Pro-Equity Strategies in 61 Gavi-Supported Countries
por: Ivanova, Vesela, et al.
Publicado: (2023)

GAVI supply chain strategy people and practice evidence review
por: Steele, Pamela
Publicado: (2014)

Lessons Learned From Implementing Prospective, Multicountry Mixed-Methods Evaluations for Gavi and the Global Fund
por: Carnahan, Emily, et al.
Publicado: (2020)

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
por: Brisson, Marc, et al.
Publicado: (2020)

Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey
por: Malarski, Maya, et al.
Publicado: (2019)

Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts
por: Jit, Mark, et al.
Publicado: (2013)

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
por: Kim, Jane J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5e7dgbb1o79vrnqj82rg7s5d6d